- Home
- ARWR
as 07-26-2024 4:00pm EST
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | PASADENA |
| Market Cap: | 3.6B | IPO Year: | 1993 |
| Target Price: | $42.71 | AVG Volume (30 days): | 923.9K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.67 - $39.83 | Next Earning Date: | 08-05-2024 |
| Revenue: | $35,473,000 | Revenue Growth: | -87.00% |
| Revenue Growth (this year): | -58.21% | Revenue Growth (next year): | 37.21% |
Stock Insider Trading Activity of Arrowhead Pharmaceuticals Inc. (ARWR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Oliver Tracie | ARWR | Chief Commercial Officer | Jul 2 '24 | Sell | $25.28 | 9,394 | $237,480.32 | 127,107 | SEC Form 4 |
| Vakiener Victoria | ARWR | Director | May 2 '24 | Sell | $23.31 | 1,799 | $41,934.69 | 30,205 | SEC Form 4 |
| Hamilton James C | ARWR | Chief Discovery/Trans Medicine | Apr 1 '24 | Sell | $28.03 | 6,000 | $168,180.00 | 204,851 | SEC Form 4 |
| Lu Hongbo | ARWR | Director | Mar 18 '24 | Buy | $27.49 | 1,000 | $27,490.00 | 31,680 | SEC Form 4 |
| Lu Hongbo | ARWR | Director | Mar 18 '24 | Buy | $28.00 | 1,000 | $28,000.00 | 32,680 | SEC Form 4 |
| Lu Hongbo | ARWR | Director | Mar 18 '24 | Buy | $27.50 | 1,000 | $27,500.00 | 33,680 | SEC Form 4 |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Jan 31 '24 | Sell | $32.16 | 37,769 | $1,214,651.04 | 3,734,778 | SEC Form 4 |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Jan 31 '24 | Sell | $32.71 | 19,730 | $645,368.30 | 3,715,048 | SEC Form 4 |
| Hamilton James C | ARWR | Chief Discovery/Trans Medicine | Jan 12 '24 | Sell | $36.47 | 4,238 | $154,559.86 | 214,553 | SEC Form 4 |
| Hamilton James C | ARWR | Chief Discovery/Trans Medicine | Jan 12 '24 | Sell | $37.37 | 3,702 | $138,343.74 | 210,851 | SEC Form 4 |
| Waddill William D. | ARWR | Director | Jan 11 '24 | Sell | $37.81 | 2,634 | $99,591.54 | 49,170 | SEC Form 4 |
| Waddill William D. | ARWR | Director | Jan 11 '24 | Sell | $38.59 | 1,300 | $50,167.00 | 47,870 | SEC Form 4 |
| Ferrari Mauro | ARWR | Director | Jan 11 '24 | Sell | $37.80 | 2,147 | $81,156.60 | 61,778 | SEC Form 4 |
| Ferrari Mauro | ARWR | Director | Jan 11 '24 | Sell | $38.63 | 1,000 | $38,630.00 | 60,778 | SEC Form 4 |
| Vakiener Victoria | ARWR | Director | Jan 11 '24 | Sell | $37.87 | 3,620 | $137,089.40 | 33,101 | SEC Form 4 |
| Vakiener Victoria | ARWR | Director | Jan 11 '24 | Sell | $38.84 | 1,100 | $42,724.00 | 32,001 | SEC Form 4 |
| GIVEN DOUGLAS B | ARWR | Director | Jan 11 '24 | Sell | $37.76 | 1,811 | $68,383.36 | 130,811 | SEC Form 4 |
| GIVEN DOUGLAS B | ARWR | Director | Jan 11 '24 | Sell | $38.55 | 1,100 | $42,405.00 | 129,711 | SEC Form 4 |
| Myszkowski Kenneth Allen | ARWR | Chief Financial Officer | Jan 4 '24 | Sell | $35.65 | 8,904 | $317,427.60 | 440,600 | SEC Form 4 |
| Myszkowski Kenneth Allen | ARWR | Chief Financial Officer | Jan 4 '24 | Sell | $34.97 | 5,800 | $202,826.00 | 449,504 | SEC Form 4 |
| Myszkowski Kenneth Allen | ARWR | Chief Financial Officer | Jan 4 '24 | Sell | $34.04 | 1,400 | $47,656.00 | 455,304 | SEC Form 4 |
| Oliver Tracie | ARWR | Chief Commercial Officer | Jan 4 '24 | Sell | $33.89 | 74 | $2,507.86 | 136,501 | SEC Form 4 |
| San Martin Javier | ARWR | Chief Medical Officer | Jan 4 '24 | Sell | $34.11 | 800 | $27,288.00 | 206,000 | SEC Form 4 |
| San Martin Javier | ARWR | Chief Medical Officer | Jan 4 '24 | Sell | $35.03 | 3,100 | $108,593.00 | 202,900 | SEC Form 4 |
| San Martin Javier | ARWR | Chief Medical Officer | Jan 4 '24 | Sell | $35.64 | 4,403 | $156,922.92 | 198,497 | SEC Form 4 |
Latest Arrowhead Pharmaceuticals Inc. News
ARWR Breaking Stock News: Dive into ARWR Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
Argus Research
3 days ago
ARWR: Lowering target price to $23.00
Argus Research
10 days ago
ARWR: Lowering target price to $24.00
Argus Research
17 days ago
ARWR: Rating decreased to a SELL
MT Newswires
22 days ago
HC Wainwright Cuts Price Target on Arrowhead Pharmaceuticals to $60 From $90, Keeps Buy Rating
Zacks Small Cap Research
25 days ago
ARWR: Moving Plozasiran Forward in Phase 3 CVOT…
Simply Wall St.
a month ago
The past three years for Arrowhead Pharmaceuticals (NASDAQ:ARWR) investors has not been profitable
MT Newswires
a month ago
Arrowhead Pharmaceuticals to Advance Investigational Medicine Plozasiran Into Late-stage Cardiovascular Study
Compare ARWR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARWR Arrowhead Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.